Elevated Myo15 level increases AZ size and terminal length. (A) Confocal images of NMJs upon Myo15 overexpression and control (UAS–Gal4 system), stained for BRP (green) and HRP (magenta), scale bar overview 5 µm, zoom 2 µm. (B–G) Quantifications of A. (B) AZ area (control 100.0 ± 2.24% n = 12; Myo15 OE 110.3 ± 3.81%, n = 12), (C) density of AZs, as number of AZ per NMJ area (control 100.0 ± 3.04%, n = 12; Myo15 OE 91.59 ± 2.82%, n = 12), (D) BRP mean pixel intensity of single AZs (control 100.0 ± 5.52%, n = 12; Myo15 OE 105.5 ± 4.49%, n = 12), (E) NMJ length (control 100.0 ± 6.02%, n = 12; Myo15 OE 145.3 ± 5.38%, n = 12). (F) Total number of all AZs per NMJ (control 100.0 ± 3.00%, n = 12; Myo15 OE 117.7 ± 3.14%, n = 12). (G) Total BRP intensity as integral of the BRP mean pixel intensity over the entire NMJ (control 100.0 ± 4.00%, n = 12; Myo15 OE 133.6 ± 6.13%, n = 12). (H) STED imaging of AZs labeled with BRP (green) upon Myo15 overexpression (UAS–Gal4 system), (scale bar 0.5 µm). (I–K) Quantification of H. (I) AZ area (control 100.0 ± 3.11%, n = 14; Myo15 OE 113.9 ± 3.51%, n = 12), (J) relative frequency histogram of AZ areas (total number AZs: control 456 and Myo15 OE 306), bin width 0.01, (K) density of AZs, as number of AZ per NMJ area (control 100.0 ± 6.84%, n = 14; Myo15 OE 95.03 ± 5.21%, n = 12). All data are provided as mean ± SEM. For B–G: n represents NMJs with 1–2 NMJs/animal from five to six animals, for I–K: n represents boutons, three to four animals with 1–2 NMJs/animal and 1–4 boutons/NMJ, *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. OE, overexpression.
Figure 3.

Elevated Myo15 level increases AZ size and terminal length. (A) Confocal images of NMJs upon Myo15 overexpression and control (UAS–Gal4 system), stained for BRP (green) and HRP (magenta), scale bar overview 5 µm, zoom 2 µm. (B–G) Quantifications of A. (B) AZ area (control 100.0 ± 2.24% n = 12; Myo15 OE 110.3 ± 3.81%, n = 12), (C) density of AZs, as number of AZ per NMJ area (control 100.0 ± 3.04%, n = 12; Myo15 OE 91.59 ± 2.82%, n = 12), (D) BRP mean pixel intensity of single AZs (control 100.0 ± 5.52%, n = 12; Myo15 OE 105.5 ± 4.49%, n = 12), (E) NMJ length (control 100.0 ± 6.02%, n = 12; Myo15 OE 145.3 ± 5.38%, n = 12). (F) Total number of all AZs per NMJ (control 100.0 ± 3.00%, n = 12; Myo15 OE 117.7 ± 3.14%, n = 12). (G) Total BRP intensity as integral of the BRP mean pixel intensity over the entire NMJ (control 100.0 ± 4.00%, n = 12; Myo15 OE 133.6 ± 6.13%, n = 12). (H) STED imaging of AZs labeled with BRP (green) upon Myo15 overexpression (UAS–Gal4 system), (scale bar 0.5 µm). (I–K) Quantification of H. (I) AZ area (control 100.0 ± 3.11%, n = 14; Myo15 OE 113.9 ± 3.51%, n = 12), (J) relative frequency histogram of AZ areas (total number AZs: control 456 and Myo15 OE 306), bin width 0.01, (K) density of AZs, as number of AZ per NMJ area (control 100.0 ± 6.84%, n = 14; Myo15 OE 95.03 ± 5.21%, n = 12). All data are provided as mean ± SEM. For B–G: n represents NMJs with 1–2 NMJs/animal from five to six animals, for I–K: n represents boutons, three to four animals with 1–2 NMJs/animal and 1–4 boutons/NMJ, *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. OE, overexpression.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal